BC
MDGL icon

Bridgefront Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bridgefront Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$284K Buy
+528
New +$270K 0.07% 394
2026
Q1 		– Sell
-393
Closed -$229K – 674
2025
Q4 		$229K Sell
393
-323
-45% -$165K 0.06% 432
2025
Q3 		$328K Sell
716
-1,427
-67% -$532K 0.1% 365
2025
Q2 		$649K Buy
+2,143
New +$639K 0.17% 209
2025
Q1 		– Sell
-1,084
Closed -$334K – 763
2024
Q4 		$334K Buy
+1,084
New +$305K 0.11% 329

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bridgefront Capital's MDGL Position: Q2 2026 in Review

Bridgefront Capital opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 528 shares worth $284K. The stake represents 0.07% of the portfolio and ranks #394 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in MDGL as recently as Q4 2025.

Bridgefront Capital first reported a position in MDGL in Q4 2024 and has held it in 5 quarters since. The position peaked at $649K in Q2 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Bridgefront Capital held 528 shares of Madrigal Pharmaceuticals worth $284K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Bridgefront Capital position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.07% of Bridgefront Capital's portfolio in Q2 2026, its #394 holding.
  • Bridgefront Capital first reported a position in Madrigal Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Bridgefront Capital's Madrigal Pharmaceuticals position peaked at $649K in Q2 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.